Wellnex Life (ASX: WNX) executive director Zack Bozinovski joins Small Caps to discuss the company's recent expansions and the receipt of key market authorisations (MA).
 
Most recently it received a MA approval for its liquid paracetamol plus caffeine soft gel.
 
That approval builds on the company's previous MAs for liquid paracetamol, liquid paracetamol plus ibuprofen and liquid mini-ibuprofen.
 
The liquid paracetamol plus caffeine soft gel approval is expected to drive additional revenue opportunities for Wellnex Life alongside the existing MAs being utilised by domestic and international companies like Chemist Warehouse and Haleon.
 
The unique product is expected to provide opportunities not only to use in the company’s own brands but also opportunities to license it to third parties.
 
Wellnex Life recently delivered its TGA registered paracetamol soft gel liquid analgesic to Haleon and the UK market.
 
The company also recently acquired leading Australian topical pain relief brand Pain Away.

In addition, Wellnex Life reported record sales of $3 million per month for November and December 2024, with 56% of the revenue coming from its own high-margin brands.

Articles:
https://smallcaps.com.au/wellnex-life-expands-global-reach-uk-market-entry-new-product-approval/
https://smallcaps.com.au/wellnex-life-reports-record-monthly-sales-pursues-dual-listing-lse/

For more information on Wellnex Life:
https://smallcaps.com.au/stocks/asx-wnx/

See omnystudio.com/listener for privacy information.